Millennium: The Takeda Oncology Co. and its Japanese parent said Wednesday that European regulators have granted conditional marketing authorization for Adcetris, a drug for some forms of lymphoma, a general term for cancers of the lymphatic system.

In a press release, Takeda Pharmaceutical Co. said it intends to launch Adcetris in Europe in coming weeks. (Takeda bought Cambridge-based Millennium in 2008 for $8.8 billion.)